全文获取类型
收费全文 | 189694篇 |
免费 | 8171篇 |
国内免费 | 357篇 |
专业分类
耳鼻咽喉 | 3369篇 |
儿科学 | 6960篇 |
妇产科学 | 4714篇 |
基础医学 | 26806篇 |
口腔科学 | 5056篇 |
临床医学 | 14618篇 |
内科学 | 35132篇 |
皮肤病学 | 5181篇 |
神经病学 | 17779篇 |
特种医学 | 9463篇 |
外国民族医学 | 26篇 |
外科学 | 31146篇 |
综合类 | 1284篇 |
一般理论 | 42篇 |
预防医学 | 9472篇 |
眼科学 | 4832篇 |
药学 | 12979篇 |
中国医学 | 383篇 |
肿瘤学 | 8980篇 |
出版年
2023年 | 853篇 |
2021年 | 1539篇 |
2020年 | 1308篇 |
2019年 | 1560篇 |
2018年 | 3407篇 |
2017年 | 2713篇 |
2016年 | 3736篇 |
2015年 | 4181篇 |
2014年 | 4329篇 |
2013年 | 6199篇 |
2012年 | 9700篇 |
2011年 | 9197篇 |
2010年 | 5247篇 |
2009年 | 4232篇 |
2008年 | 8747篇 |
2007年 | 9699篇 |
2006年 | 9674篇 |
2005年 | 10003篇 |
2004年 | 9515篇 |
2003年 | 9282篇 |
2002年 | 9179篇 |
2001年 | 6608篇 |
2000年 | 6662篇 |
1999年 | 5815篇 |
1998年 | 1700篇 |
1997年 | 1398篇 |
1996年 | 1068篇 |
1995年 | 898篇 |
1994年 | 843篇 |
1992年 | 2599篇 |
1991年 | 2536篇 |
1990年 | 2446篇 |
1989年 | 2309篇 |
1988年 | 2021篇 |
1987年 | 2018篇 |
1986年 | 1871篇 |
1985年 | 1818篇 |
1984年 | 1402篇 |
1983年 | 1149篇 |
1979年 | 1486篇 |
1978年 | 1093篇 |
1977年 | 922篇 |
1975年 | 1181篇 |
1974年 | 1208篇 |
1973年 | 1101篇 |
1972年 | 1114篇 |
1971年 | 1078篇 |
1970年 | 950篇 |
1969年 | 891篇 |
1968年 | 876篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
Irmak Karaca Suzan Güven Yılmaz Melis Palamar Halil Ateş 《Ocular immunology and inflammation》2020,28(6):947-951
ABSTRACT
Purpose
To investigate the effect of 1% tropicamide on anterior chamber aqueous flare (ACAF) measurements acquired with laser flare meter in patients with pseudoexfoliation. 相似文献53.
54.
控便功能是指当产生便意时,可以辨别粪便干稀急缓,并能正常控制其排出的能力.因一些意外因素,如盆底功能障碍、某些先天性疾病及盆腔恶性肿瘤术后会导致此功能受损,而严重影响患者的生活质量.近年来,诸多国内外学者对控便功能障碍患者进行了临床和影像学研究,能够认知控便功能受损的造成因素及改善方法,对于术前术后制定治疗方案具有重要的临床价值,是目前研究的焦点.以MRI从影像学角度为阐述其障碍发生的可能机制及改善预后提供一定依据.因此,笔者对近年来控便功能障碍的MRI研究进展做简要综述. 相似文献
55.
56.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
57.
中药(单体/复方)药效物质基础研究是中医药现代研究的关键问题之一。然而,目前运用的生化和分子生物学方法很难诠释其多靶点、整体性和动态性的整合调节作用。课题组提出的"证治代谢组学"假说理论指出,不同的证候存在"证相关代谢谱群"和"证相关生物标志物",这可能是中药药效物质基础所在,辨证论治后偏离的代谢网络功能呈现回归趋势。基于"证治代谢组学"假说开展中药(单体/复方)药效物质基础研究,这将为阐释中药(单体/复方)防病治病和养生保健的科学内涵及其对疾病个体的整合调节作用提供新的思路。本文以冠心病为研究载体、气阴虚血瘀证为切入点、活血保心丸为干预措施,就该研究思路的内涵与总体模式、提出的背景与依据、实践的方式与可行性、创新与特色及其研究意义等进行了简要介绍。 相似文献
58.
Der Freie Zahnarzt - Risiken und Nebenwirkungen im Gesundheitswesen. Wer sich heute mit Digitalisierung beschäftigt, kommt am Thema „Künstliche Intelligenz (KI)“ nicht vorbei.... 相似文献
59.
Uwe Schneider PhD Antony Lomax Peter Pemler Jürgen Besserer Dieter Ross Norbert Lombriser Barbara Kaser-Hotz 《Strahlentherapie und Onkologie》2006,182(11):647-652
BACKGROUND AND PURPOSE: There is concern about the increase of radiation-induced malignancies with the application of modern radiation treatment techniques such as intensity-modulated radiotherapy (IMRT) and proton radiotherapy. Therefore, X-ray scatter and neutron radiation as well as the impact of the primary dose distribution on secondary cancer incidence are analyzed. MATERIAL AND METHODS: The organ equivalent dose (OED) concept with a linear-exponential and a plateau dose-response curve was applied to dose distributions of 30 patients who received radiation therapy of prostate cancer. Three-dimensional conformal radiotherapy was used in eleven patients, another eleven patients received IMRT with 6-MV photons, and eight patients were treated with spot-scanned protons. The treatment plans were recalculated with 15-MV and 18-MV photons. Secondary cancer risk was estimated based on the OED for the different treatment techniques. RESULTS: A modest increase of 15% radiation-induced cancer results from IMRT using low energies (6 MV), compared to conventional four-field planning with 15-MV photons (plateau dose-response: 1%). The probability to develop a secondary cancer increases with IMRT of higher energies by 20% and 60% for 15 MV and 18 MV, respectively (plateau dose-response: 2% and 30%). The use of spot-scanned protons can reduce secondary cancer incidence as much as 50% (independent of dose-response). CONCLUSION: By including the primary dose distribution into the analysis of radiation-induced cancer incidence, the resulting increase in risk for secondary cancer using modern treatment techniques such as IMRT is not as dramatic as expected from earlier studies. By using 6-MV photons, only a moderate risk increase is expected. Spot-scanned protons are the treatment of choice in regard to secondary cancer incidence. 相似文献
60.
Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. 总被引:1,自引:0,他引:1
Samer Ezziddin Timur Logvinski Charlotte Yong-Hing Hojjat Ahmadzadehfar Hans-Peter Fischer Holger Palmedo Jan Bucerius Michael J Reinhardt Hans-Jürgen Biersack 《Journal of nuclear medicine》2006,47(2):223-233
Radiolabeled octreotide analogs (Oct) and metaiodobenzylguanidine (MIBG) offer 2 different approaches for imaging and targeting metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET). Despite successful establishment of the revised World Health Organization (WHO) classification, which distinguishes between low- and high-grade malignant GEP-NET, there is a lack of scintigraphic studies comparing uptake behavior on the basis of this categorization. This study aims to define predisposing factors of tracer uptake for both imaging principles implementing the updated tumor criteria of the current WHO classification. METHODS: Fifty-seven consecutive patients with histologically confirmed metastatic GEP-NET evaluated with both 111In-pentetreotide and 123I/131I-MIBG scintigraphy were included in this study. Intensity of tracer uptake was graded according to the different metastatic regions. Patients were classified as overall positive when avid uptake in the clinically relevant tumor lesions was present. Correlation was tested between the proportion of positive patients and tumor origin, function, and malignancy. RESULTS: Overall, 52 patients (91.2%) were Oct positive and 28 patients (49.1%) were MIBG positive. The proportion of tracer-positive patients was significantly higher (P < 0.05) in low-grade malignant tumors for both tracers and in functioning as well as in gastroenteral NET for MIBG. Five patients were negative for both tracers. None of the Oct-negative patients proved to be MIBG positive. CONCLUSION: Oct affinity is observed with high frequency throughout the subgroups of metastatic GEP-NET, whereas corresponding MIBG uptake is overall less prevalent and more group dependent. Tumor differentiation significantly impacts both Oct and MIBG uptake, whereas functionality predisposes only for MIBG accumulation. Though clearly inferior to Oct-based radioimaging in most GEP-NET, MIBG achieves a remarkable rate of radioligand accumulation in functioning midgut enterochromaffin cell metastases (>80% of patients positive). These results may have implications for patient management and potentially for selection and performance of targeted therapy. 相似文献